Simmiparib

Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC 50 values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib . Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis . Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts In Vitro Simmiparib (0-10 μM; 3 days) exhibits anti-proliferative activity against various cancer cells. Simmiparib (0-10 μM; 48 h) induces typical G2/M arrest in Capan-1 cells. Simmiparib (0.1-2 μM; 24 h) induces apoptosis in MDA-MB-436 and V-C8 (BRCA2 -/- ) cells, and increases dose-dependently the levels of γH2AX. Simmiparib (1-10 μM; 48 h or 72 h) increases the phosphorylation levels of Chk1 and Chk2 and the protein levels of p-Cyclin B1 (S147), Cyclin B1, p-CDK1 (Y15) and CDK1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Various cancer cells harboring deficient BRCA1, BRCA2, PTEN and EWS-FLI1 Concentration: 0-10 μM Incubation Time: 3 days Result: Exhibited anti-proliferative activity against MDA-MB-436 (BRCA1 -/- ), RD-ES (EWS-FLI1), DoTc2-4510 (BRCA2 -/- ), Capan-1 (BRCA2 -/- ) and U251 (PTEN -/- ) with IC 50 s of 0.2 nM, 4.6 nM, 20 nM, 21 nM and 36 nM, respectively. Cell Cycle AnalysisCell Line: Capan-1 cells Concentration: 0, 1, 3 and 10 μM Incubation Time: 48 h Result: Induced typical G2/M arrest in a concentration-dependent manner. Apoptosis AnalysisCell Line: MDA-MB-436 Concentration: 0.1 and 1 μM Incubation Time: 24 h Result: Led to 39.64% and 42.98% apoptosis at 0.1 and 1 μM, respectively. Increased dose-dependently the levels of γH2AX. Apoptosis AnalysisCell Line: V-C8 (BRCA2 -/- ) Concentration: 0.5 and 2 μM Incubation Time: 24 h Result: Caused more than 57% apoptosis. Western Blot AnalysisCell Line: Capan-1 Concentration: 1 and 10 μM Incubation Time: 48 h or 72 h Result: Increased the phosphorylation levels of Chk1 and Chk2 but did not change the levels of the corresponding total proteins. Increased the protein levels of p-Cyclin B1 (S147), Cyclin B1, p-CDK1 (Y15) and CDK1. In Vivo Simmiparib (2, 4 and 8 mg/kg; p.o.; qd, for 14 days) inhibits the growth of tumor in V-C8 (BRCA2 -/- ) and MDA-MB-436 (BRCA2 -/- ) xenograft mice models . Simmiparib (10 and 50 mg/kg; p.o.; qd, for 42 days) inhibits the growth of BRCA1-mutated breast cancer in xenograft mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/cA nude mice (Subcutaneously injected with BRCA2 -/- V-C8 cells and BRCA2 -/- MDA-MB-436 cells) Dosage: 2, 4 and 8 mg/kg Administration: p.o.; qd, for 14 days Result: Apparently inhibited the growth of the V-C8 tumor with an inhibition rate of 74.53% at 8 mg/kg. Suppressed the growth of the BRCA1-deficient MDA-MB-436 xenografts in a dose-dependent manner with its average inhibition rates of 64.93, 82.98 and 85.79% at 2, 4 and 8 mg/kg. Did not cause significant loss of body weight. Animal Model: Female BALB/cA nude mice (Subcutaneously injected with cancer cells derived from BRCA1-mutated BR-05-0028 breast cancer tissue) Dosage: 10 and 50 mg/kg Administration: p.o.; qd, for 42 days Result: Elicited dose-dependent growth inhibition with the inhibition rate of 76.73% and 93.82% at 10 mg/kg and 50 mg/kg, respectively. Form:Solid IC50& Target:PARP1 0.74 nM (IC 50 ) PARP2 0.22 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet